This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with
immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in
three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and
relatlimab 160mg) will be given every 4 weeks for two years
Additional locations may be listed on ClinicalTrials.gov for NCT05077280.
See trial information on ClinicalTrials.gov for a list of participating sites.
Metastatic uveal melanoma has no standard therapy, but there is evidence that both
radiation therapy and immunotherapy may be helpful and may be synergistic. This is a
phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with
Opdualag (nivolumab 480mg and relatlimab 160mg) for up to two years. SBRT will be given
in three doses of 15Gy each to 1-5 separate metastases, limiting the total dosage to
700cc's of normal liver to <15Gy. Opdualag (nivolumab 480mg and relatlimab 160mg) will be
given every 4 weeks for two years. Objectives are to determine the safety and
tolerability, and iRECIST will be used to determine responses.We will treat up to 50
patients.
Lead OrganizationCalifornia Pacific Medical Center-Pacific Campus
